

Mice Model Technologies Market Expansion Targeting USD 3.2 Billion by 2031 | Transparency Market Research

Increase in R&D in gene technology due to the need for accurate and speedy treatment of various diseases and rise in adoption of advanced genomic techniques

WILMINGTON, DELAWARE, UNITED STATES, September 7, 2023 /EINPresswire.com/ -- Transparency Market Research published latest research study on "[Mice Model Technologies Market](#) Size Report, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2031 - Global Analysis by Technology and End User", the global market size is expected to reach USD 3.2 billion by 2031 from USD 1.6 billion in 2021, it is estimated to grow with a CAGR of 7.4 % from 2022-2031.



□□□□□□ □□□□ □□□□□□□□□□□□ □□□□□□: □□□□□□ □□□□□□□□

The necessity for developing biomedical research methodologies is being driven by the prevalence of chronic disorders. The market for mice model technologies is advancing due to the expanding usage of mice models to simulate human diseases.

The introduction of CRISPR-based methods and a variety of cutting-edge molecular genome-altering technologies has opened up a world of possibilities. Genetically modified mouse models are effectively produced using techniques and technologies.

□□□□□□ □□□□□□ □□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□ □□□□□□ -

BIOCYTOGEN

Charles River Laboratories

Cyagen Biosciences

Gempharmatech

genOway

ingenious targeting laboratory

Merck KGaA

Ozgene Pty Ltd.

Taconic Biosciences, Inc.

PolyGene AG

THE JACKSON LABORATORY

Yale School of Medicine

University of North Carolina

University of Nebraska Medical Center

Monash University

UMass Chan Medical School

University of Bonn

Columbia University

The University of Arizona

□□□□□□ □□ □□□□□ □□□□ □□□□□□□□ □□ □□ □□□□□ □□ □□□□□□□□ □□□□ □□□□□□

-https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=84893

□□□□ □□□□□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□:

Predictive Validity: Mice Model Technologies closely mimic human physiology, genetics, and immune responses, providing a more accurate representation of human disease progression and treatment outcomes. This predictive validity enhances the reliability of preclinical data and improves the likelihood of successful translation to clinical trials.

Reduced Ethical Concerns: Using Mice Model Technologies reduces the need for animal testing on non-human species, addressing ethical concerns and promoting more human research practices.

Personalized Medicine: These models can be customized to replicate specific patient profiles or disease conditions, enabling personalized medicine approaches for tailored treatment strategies.

Drug Efficacy and Safety Screening: Mice Model Technologies allow for rigorous assessment of drug efficacy and safety before progressing to human clinical trials, reducing the risk of adverse effects and optimizing the drug development process.

Understanding Disease Mechanisms: By closely resembling human biology, these models offer valuable insights into disease mechanisms and underlying molecular pathways, advancing our understanding of complex diseases.

Rapid and Cost-Effective Research: Mice Model Technologies can accelerate research timelines by providing faster results compared to traditional animal models. This efficiency reduces overall research costs and expedites the discovery of novel therapies.

Translatability to Humans: The ability of Mice Model Technologies to recapitulate human responses enhances the likelihood of successful translation of research findings to human patients, fostering more effective treatments.

Targeted Therapies: Mice Model Technologies facilitate the evaluation of targeted therapies by replicating the specific molecular targets present in human diseases, aiding in the development of precision medicine approaches.

Infectious Disease Research: Mice Model Technologies are particularly valuable in studying infectious diseases, allowing researchers to study pathogen-host interactions and test potential vaccines and antiviral treatments.

Academic and Industry Collaboration: The widespread adoption of Mice Model Technologies fosters collaboration between academic institutions, pharmaceutical companies, and biotech firms, encouraging a dynamic exchange of knowledge and resources to advance medical

research collectively.

□□□ □□ □□□ □□□□□□□ □□ □□□□ □□□□□□ □□□□□□ □□□□ □□□□ □□□□□□ -

https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=84893

□□□□□□ □□□□□□□□□□□□

□□□□□□□□□□

CRISPR Knockout

CRISPR Knockin

Random Insertions

Large, Targeted Insertions

ES Cell Modification (Homologous Recombination)

Others

□□□-□□□□

Pharmaceutical Companies

Biotechnology Companies

Academic and Research Facilities

Contract Research and Manufacturing Organizations

□□□□□□□□ □□□□□□□□

North America

Latin America

Europe

Asia Pacific

Middle East & Africa

□□□□□ □□□□□□□□

A comprehensive overview of the current and future global markets for Mice Model Technologies

Highlights of upcoming market opportunities and trends driving and restricting growth of global Mice Model Technologies market and its sub-segments, and major regions and countries involved in the market developments

In-depth information (facts and figures) concerning major market dynamics, technology advancements, regulatory aspects, and various macroeconomics factors influencing the demand and progress of this market

Identification of the companies engaged in research and development (R&D) of production, emerging technologies, and a SWOT analysis of leading competitors and their market penetration.

□□□□ □□□□□□□□ □□□□□□ □□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□ -

[Intravascular Ultrasound \[IVUS\] Devices Market](#) to Grow at a 5.9% CAGR from 2023 to 2031, reaching USD 1240 million

[Dental 3D Printing Market](#) to register a 9% CAGR from 2023 to 2031, expected to accumulate a Valuation of USD 2.9 billion

Nikhil Sawlani
Transparency Market Research Inc.
+1 518-618-1030

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/654344269>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.